Global Bloodstream Infection Testing Market, by Product Type (Instruments, Reagents, and Others), by Technology (Conventional Testing and Non-conventional Testing), by Test Type (Conventional Blood Culture Tests, PCR Method, Nucleic Acid Testing, Mass Spectroscopy, and Point-of-Care Testing), by End User (Hospitals, Independent Diagnostics Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$ 3,758.7 million in 2017, and is projected to exhibit a CAGR of 8.4% over the forecast period (2019 – 2026), as highlighted in a new report published by . Increasing prevalence of abdominal infection, dental infection, kidney and urinary infection, and chronic diseases is expected to augment the market growth Increasing prevalence of abdominal infection and dental infection and growing geriatric population are factors fueling the market growth. The Global Burden of Disease Study 2016 estimated that oral disease affects half of the world’s population i.e. 3.58 million people with dental carries. Globally it is estimated that 2.4 billion people suffer from carries of permanent teeth. Moreover, high incidences of burns/wounds cases, HIV, pneumonia, pyelonephritis, and cancer along with growing awareness about hygiene is also expected to boost the global blood stream infection testing market growth. According to World Health Organization, at the end of 2017, approximately 36.9 million people living with HIV and 1.8 million people becoming newly infected in 2017 globally. Furthermore, advancements in diagnostic testing is expected to fuel the market growth over the forecast period. For instance, in 2017, researchers from the University of Illinois and Charle Foundation Hospital completed a clinical study of a device that can detect sepsis from a single drop of blood. In April 2017, BioMérieux, a major player in the field of in vitro diagnostics, announced that BacT/ALERT VIRTUO, its fully automated blood culture system, received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This innovative blood culture microbial detection system enhances the blood culture performance for rapid detection, thereby offering faster identification of bloodstream infection. Browse 22 Market Data Tables and 20 Figures spread through 178 Pages and in-depth TOC on “Blood stream Infection Testing Market”- Global Forecast to 2026, by Product Type (Instruments, Reagents, and Others), by Technology (Conventional Testing and Non-Conventional Testing), by Test Type (Conventional Blood Culture Tests, PCR Method, Nucleic Acid Testing, Mass Spectroscopy, and Point-of-Care Testing), by End User (Hospitals, Independent Diagnostics Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) To know the latest trends and insights prevalent in the blood stream infection testing market, click the link below: https://www.coherentmarketinsights.com/market-insight/blood-stream-infection-testing-market-1727 Key players in the market are focused on launching new tests for detection of various infectious diseases. For instance, in October 2018, Becton, Dickson and Company launched the molecular test to detect the tuberculosis and multidrug resistant tuberculosis. Key Takeaways of the Blood stream Infection Testing Market:
- The global blood stream infection testing market is expected to exhibit a CAGR of 8.4% over the forecast period, owing to high prevalence of abdominal infections, dental infections, and chronic diseases
- Among product type, the instruments segment held dominant position in the blood stream infection testing market in 2018, owing to various new innovations by the key players for synthesizing bloodstream infection tests to detect the infectious diseases.
- Major companies operating in the global blood stream infection testing market include, bioMérieux SA, Becton,Dickinson and Company, AB Sciex, IRIDICA, Abbot Laboratories, Cepheid Inc., C. R. Bard, Inc., F. Hoffmann-La Roche AG, Nanoshpere, Dade Behring, AdvanDX, Siemens Healthcare.
